Wednesday, November 13, 2019
- 9:00AM-10:30AM
-
Abstract Number: 2879
Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients
6W014: Spondyloarthritis Including Psoriatic Arthritis – Clinical VII: Psoriatic Arthritis Treatment (2876–2881)- 9:00AM-10:30AM
-
Abstract Number: 2866
Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus
6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)- 9:00AM-10:30AM
-
Abstract Number: 2889
From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
6W017: Health Services Research II: Health Economics (2888–2893)- 9:00AM-10:30AM
-
Abstract Number: 2876
Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Arthritis Patients
6W014: Spondyloarthritis Including Psoriatic Arthritis – Clinical VII: Psoriatic Arthritis Treatment (2876–2881)- 9:00AM-10:30AM
-
Abstract Number: 2862
Hypoxia Resistant Pathogenic B Cells Accumulate in the RA Synovial Tissue in a CXCR3 Dependent Manner
6W012: RA – Etiology & Pathogenesis II (2858–2863)- 9:00AM-10:30AM
-
Abstract Number: 2863
Increased Expression of Extracellular Matrix Proteins in Human Fibroblast Synoviocytes and Lung Epithelial Cells Following Malondialdehyde-Acetaldehyde Adduct (MAA)/Citrullinated Protein Stimulation
6W012: RA – Etiology & Pathogenesis II (2858–2863)- 9:00AM-10:30AM
-
Abstract Number: 2893
Long-term Clinical and Economic Benefits of a Short-term Physical Activity Intervention Among Inactive Knee Osteoarthritis Patients in US: A Model-based Evaluation
6W017: Health Services Research II: Health Economics (2888–2893)- 9:00AM-10:30AM
-
Abstract Number: 2861
Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA
6W012: RA – Etiology & Pathogenesis II (2858–2863)- 9:00AM-10:30AM
-
Abstract Number: 2892
Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
6W017: Health Services Research II: Health Economics (2888–2893)- 9:00AM-10:30AM
-
Abstract Number: 2867
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)- 9:00AM-10:30AM
-
Abstract Number: 2870
Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response
6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)- 9:00AM-10:30AM
-
Abstract Number: 2860
Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
6W012: RA – Etiology & Pathogenesis II (2858–2863)- 9:00AM-10:30AM
-
Abstract Number: 2886
Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries
6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)- 9:00AM-10:30AM
-
Abstract Number: 2882
Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life